(Submitter supplied) To understand the development of new psoriasis lesions, we studied a group of moderate-to-severe psoriasis patients who experienced a relapse after ceasing efalizumab (anti-CD11a, Raptiva, Genentech). There were increased CD3+ T cells, neutrophils, CD11c+ and CD83+ myeloid DCs, but no increase in CD1c+ resident myeloid DCs. In relapsed lesions, there were many CD11c+CD1c-, inflammatory myeloid DCs identified by TNFSF10/TRAIL, TNF, and iNOS.
more...- Organism:
- Homo sapiens
- Type:
- Expression profiling by array
- Dataset:
-
GDS4606
- Platform:
- GPL571
- 14 Samples
Download data: CEL